Contact this trialFirst, we need to learn more about you.
Immunotoxin
Moxetumomab + Rituximab/Ruxience for Hairy Cell Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing the safety of combining two drugs, Rituximab/Ruxience and Moxetumomab pasudotox, to treat hairy cell leukemia or a variant of it. Eligible participants must be 18 or older and the cancer must not have responded to standard therapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service